ABOUT US
At Myeloid, we have applied our extensive knowledge of advanced gene and cell therapies to build novel platform technologies and unleash the power of myeloid cells in cancer.
Our proprietary ATAK™ platform is designed to provide clinical solutions by matching therapeutic modalities to disease conditions, including by using autologous cell therapies, in vivo cell programming using mRNA, RNA-based gene-editing using RetroT™ and multi-targeted biologics. We have translated the learnings from our backgrounds and our novel platform to create a clinical-stage, mRNA-immunotherapy pipeline focused on breakthrough therapies for cancer and autoimmune diseases.
The
Myeloid is powered by the discoveries of our founders – a group of world-leading scientists whose expertise spans oncology, immunology, mRNA biology, cell therapy, synthetic biology, and gene delivery.
We’re building a team of talented, driven scientists and other biotech industry experts to turn these discoveries into novel, life-saving treatments for people navigating life with cancer.
TEAM
LEADERSHIP
INVESTORS
SCIENTIFIC ADVISORY BOARD
Clinical Cell
Therapy Advisors
Immunology, Virology & Myeloid Cell Advisors
